Kairos Pharma

Q2 FY2026 EarningsQ2 FY26 bottom-line results exceeded consensus estimates: GAAP EPS of -$0.06 beat the -$0.08 expectation, and GAAP Net Loss of $1.39M was narrower than the anticipated $1.82M. Revenue remained at $0, in line with expectations for a clinical-stage biotech. Despite the earnings beat driven by lower-than-projected operating expenses, management maintained a 'going concern' warning as cash reserves of $2.6M are insufficient to fund operations for the next 12 months.